• 

   

  SMART.
  FOCUSED.
  PROFESSIONAL.

SMART.
FOCUSED.
PROFESSIONAL.

 

OUR MISSION

Developing innovative compounds that
stimulate therapeutic cell-signaling processes
for the treatment of neurodegenerative diseases.

Immunity Pharma’s initial focus is ALS (Lou Gehrig's disease).

 

OUR MISSION

Developing innovative compounds that
stimulate therapeutic cell-signaling processes
for the treatment of neurodegenerative diseases.

Immunity Pharma’s initial focus is ALS (Lou Gehrig's disease).

OUR LATEST NEWS

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

 Jerusalem, Israel, April 7, 2025

 

The results of a phase-2a clinical trial of IPL344 were published in Muscle and Nerve, the leading American scientific journal specializing in ALS and neuromuscular diseases.

• Results from phase 2a trial in ALS patients were

...

Read More

Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Jerusalem, Israel, January 16, 2024

• Treatment with IPL344 was well tolerated
• Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression (p=0.028); and 64% slower progression when adjusted for disease stage and rate (p=0.034)
• Study suggests benefits in weight gain, respiration, and survival
• Plasma neurofilament (NfL) reduction observed following IPL344 treatment

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced

...

Read More